AI predicts drug failure in rare blood cancer study
NCT ID NCT05853458
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 34 times
Summary
This study aimed to confirm if two simple blood test results—hemoglobin below 15.5 g/dL and a high red blood cell distribution width—could predict which patients with polycythemia vera would not respond well to the drug hydroxyurea. Researchers planned to follow 76 adults starting hydroxyurea for the first time. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Heidelberg, Baden-Wurttemberg, 69115, Germany
-
Novartis Investigative Site
Kronach, Bavaria, 96317, Germany
-
Novartis Investigative Site
Straubing, Bavaria, 94315, Germany
-
Novartis Investigative Site
Langen, Hesse, 63225, Germany
-
Novartis Investigative Site
Lingen, Lower Saxony, 49808, Germany
-
Novartis Investigative Site
Aachen, North Rhine-Westphalia, 52064, Germany
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50674, Germany
-
Novartis Investigative Site
Dortmund, North Rhine-Westphalia, 44309, Germany
-
Novartis Investigative Site
Velbert, North Rhine-Westphalia, 42551, Germany
-
Novartis Investigative Site
Saarbrücken, Saarland, 66113, Germany
-
Novartis Investigative Site
Merseburg, Saxony-Anhalt, 06217, Germany
-
Novartis Investigative Site
Berlin, 10407, Germany
-
Novartis Investigative Site
Donauwörth, 86609, Germany
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Erding, 85435, Germany
-
Novartis Investigative Site
Gütersloh, 33332, Germany
-
Novartis Investigative Site
Hanover, 30161, Germany
-
Novartis Investigative Site
Kiel, 24105, Germany
-
Novartis Investigative Site
Mutlangen, 73557, Germany
-
Novartis Investigative Site
Naunhof, 04683, Germany
-
Novartis Investigative Site
Würselen, 52146, Germany
Conditions
Explore the condition pages connected to this study.